Navigation Links
Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR
Date:4/1/2008

HILTON HEAD ISLAND, S.C., April 1 /PRNewswire/ -- Dr. Roger Kenneth Hershline, PhD, MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to the funder community, including funding initiatives such as the Grand Challenges in Global Health initiative. The monies would be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World AIDS Day Conference in China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.

"I am thinking in terms of problem solving. Traditional commercial drug design and projects funding from the NIH has completely ignored this approach to date," stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Dr. Hershline is hopeful that the foundation community, including the Grand Challenges in Global Health initiative, looks into the work and progress that he has made towards solving this problem and fills the gap in funding.

Dr. Hershline has a doctorate degree in drug design and a medical degree. Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially lifesaving invention, LiSAVIOR remains completely un-funded.

Interested parties can contact Dr. Roger Kenneth Hershline, PhD, MD, thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail: P.O. Box 23467, Hilton Head Is., SC, 29925, fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.

Web site: http://www.curehiv.us

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
2. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
3. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
4. Genmab Reaches Milestones in Ofatumumab Collaboration
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Fralex reaches 100th patient milestone in fibromyalgia study
7. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
8. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
9. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
10. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
11. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
Breaking Biology News(10 mins):